Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Identification of biomarkers using single cell technology that inform on targeted and immune therapy treatment in melanoma
EF 2022-23
Résumé
Skin cancer is the most common type of cancer in North America. Melanoma, although representing only 1% of all skin cancers, accounts for the majority of all skin-cancer related fatalities. Melanoma incidence and death rates are one of the fastest-rising out of all cancers, killing 1200 Canadians each year. Recent advances in targeted therapies and immunotherapies, which stop cancer cells from growing and re-activate the immune system to fight cancer cells, have led to impressive survival benefits for patients. However, these treatments only work for a small proportion of patients and do not always have lasting results (i.e. the cancer often returns). Many patients taking immunotherapies also experience immune-related adverse events (i.e. inflammatory auto-immune conditions) that can have serious consequences. Recent studies on melanoma indicate that measuring interactions between immune cells and melanoma cancer cells can inform on a patient's response to targeted therapy or immunotherapy; however, no predictive markers exist for clinical use. During my PhD studies, I will employ cutting-edge imaging and molecular profiling technologies to look inside the tumor and characterize the immune-cell landscape of melanoma and its surrounding supportive tissues, known as the tumor microenvironment. I will then utilize advanced statistical methods to integrate these data to discover new markers that will predict patient response to targeted and immune therapies, to improve patient outcomes and quality of life, and to ensure patients receive the right care, thus increasing melanoma survival rates and reducing unnecessary costs in the healthcare system.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475801
Name
Magrill Jamie A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identification of biomarkers using single cell technology that inform on targeted and immune therapy treatment in melanoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Imaging Mass Cytometry; Immunology; Immunotherapy; Melanoma; Targeted Therapy; Tumor Immune Microenvironment
Abstract
Skin cancer is the most common type of cancer in North America. Melanoma, although representing only 1% of all skin cancers, accounts for the majority of all skin-cancer related fatalities. Melanoma incidence and death rates are one of the fastest-rising out of all cancers, killing 1200 Canadians each year. Recent advances in targeted therapies and immunotherapies, which stop cancer cells from growing and re-activate the immune system to fight cancer cells, have led to impressive survival benefits for patients. However, these treatments only work for a small proportion of patients and do not always have lasting results (i.e. the cancer often returns). Many patients taking immunotherapies also experience immune-related adverse events (i.e. inflammatory auto-immune conditions) that can have serious consequences. Recent studies on melanoma indicate that measuring interactions between immune cells and melanoma cancer cells can inform on a patient's response to targeted therapy or immunotherapy; however, no predictive markers exist for clinical use. During my PhD studies, I will employ cutting-edge imaging and molecular profiling technologies to look inside the tumor and characterize the immune-cell landscape of melanoma and its surrounding supportive tissues, known as the tumor microenvironment. I will then utilize advanced statistical methods to integrate these data to discover new markers that will predict patient response to targeted and immune therapies, to improve patient outcomes and quality of life, and to ensure patients receive the right care, thus increasing melanoma survival rates and reducing unnecessary costs in the healthcare system.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Magrill, Jamie A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~